Skip to content

US · SNTI · BIOTECHNOLOGY

Senti Biosciences, Inc. (SNTI) intrinsic value and stock valuation

$1.77as of 2026-11-21 · Mkt cap 11.62M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Senti Biosciences, Inc. DCF and intrinsic value

InvestorsCraft values SNTI with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SNTI’s statements →

Senti Biosciences, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology South San Francisco, CA 94080 sentibio.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$20K-44.8% 5y CAGRd
20192025
Net income
-$-61.44M
20192025
Free cash flow
-$-43.64M
20192025
Total equity
$5.59M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$20K$0.00$1.98M$3.29M$2.29M
Operating income-$-63.73M-$-61.04M-$-92.73M-$-62.08M-$-40.45M
Net income-$-61.44M-$-52.79M-$-71.06M-$-58.21M-$-55.32M
EPSd-$-273.27K-$-11.48M-$-16M-$-13.26M-$-12.66M
Operating cash flow-$-43.44M-$-41.4M-$-52.4M-$-34.9M-$-34.63M
Capital expenditure-$-200K-$-30K-$-12.04M-$-41.37M-$-5.54M
Free cash flow-$-43.64M-$-41.42M-$-64.43M-$-76.27M-$-40.18M
Total assets$51.2M$97.8M$119.5M$180.8M$96.7M
Total debt$28.9M$33.6M$37.7M$37.1M$22.7M
Net debt$12.5M-$-14.64M$1.74M-$-20.53M-$-33.3M
Total equity$5.59M$25.7M$66.9M$127.3M$60.4M
Cash and short-term investments$16.4M$48.3M$35.9M$98.6M$56M
Income statement
20252024202320222021
Revenue$20K$0.00$1.98M$3.29M$2.29M
Cost of revenue$3.64M$0.00$0.00$0.00$0.00
Gross profit-$-3.62M$0.00$1.98M$3.29M$2.29M
Research and development expenses$37.6M$34.4M$32.2M$28.1M$22M
Selling, general and administrative expenses$26.2M$23.5M$34.9M$37.6M$21.3M
Other expenses-$-3.64M$3.17M$27.7M-$-410K-$-470K
Operating expenses$60.1M$61M$94.7M$65.4M$42.7M
Cost and expenses$63.8M$61M$94.7M$65.4M$42.7M
Interest income$930K$950K$2.86M$1.7M$10K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$3.64M$5.85M$5.43M$3.92M$3.01M
Ebitda-$-57.8M-$-54.88M-$-61.34M-$-45.74M-$-52.31M
Operating income-$-63.73M-$-61.04M-$-92.73M-$-62.08M-$-40.45M
Total other income/expenses, net$2.29M$8.25M$9.32M$12.4M-$-14.87M
Income before tax-$-61.44M-$-52.79M-$-83.41M-$-49.66M-$-55.32M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-61.44M-$-52.79M-$-71.06M-$-58.21M-$-55.32M
Weighted average shares outstanding$224.8M$4.6M$4.44M$4.39M$4.37M
Weighted average diluted shares outstanding$224.8M$4.6M$4.44M$4.39M$4.37M
Balance sheet
20252024202320222021
Cash and short-term investments$16.4M$48.3M$35.9M$98.6M$56M
Net receivables$1.59M$1.8M$17.7M$630K$480K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$23.3M$59M$71.2M$102.6M$58.8M
Property, plant and equipment, net$24.4M$35.2M$41.6M$74.6M$33.1M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$3.53M$0.00$4.64M$3.37M$3.26M
Total non-current assets$28M$38.9M$48.3M$78.2M$38M
Total assets$51.2M$97.8M$119.5M$180.8M$96.7M
Accounts payable$2.94M$1.45M$1.25M$2.27M$5.19M
Short-term debt$5.33M$4.75M$4.13M$1.99M$1.74M
Deferred revenue$350K$660K$990K$800K$1.66M
Total current liabilities$14M$13.2M$12.7M$18.1M$14.5M
Long-term debt$23.6M$28.9M$33.5M$35.1M$21M
Deferred revenue, non-current$7.95M$0.00$0.00$0.00$180K
Total non-current liabilities$31.7M$59.1M$39.9M$35.5M$21.8M
Capital lease obligations$28.9M$33.6M$37.7M$37.1M$21M
Total liabilities$45.6M$72.2M$52.6M$53.5M$36.3M
Common stock$0.00$0.00$10K$0.00$0.00
Retained earnings-$-358.57M-$-297.13M-$-244.34M-$-173.29M-$-115.08M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$5.59M$25.7M$66.9M$127.3M$60.4M
Total investments$3.53M$0.00$4.64M$44.3M$3.26M
Total debt$28.9M$33.6M$37.7M$37.1M$22.7M
Net debt$12.5M-$-14.64M$1.74M-$-20.53M-$-33.3M
Cash flow statement
20252024202320222021
Net income-$-61.44M-$-52.79M-$-71.06M-$-58.22M-$-55.32M
Depreciation and amortization$3.64M$5.85M$5.43M$3.92M$3.01M
Stock-based compensation$5.71M$1.75M$9.67M$16.4M$2.29M
Change in working capital$3.56M$4.04M$4.67M$13.9M$610K
Accounts receivable$210K-$-730K-$-930K-$-130K-$-400K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$1.74M$800K-$-290K$190K-$-620K
Net cash provided by operating activities-$-43.44M-$-41.4M-$-52.4M-$-34.9M-$-34.63M
Investments in property, plant and equipment-$-200K-$-30K-$-12.04M-$-41.37M-$-5.54M
Acquisitions, net$10K$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-180K$30K$30.1M-$-81.96M-$-5.54M
Common stock issued$8.71M$49.1M$510K$730K$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$11.8M$53.7M$780K$118.6M$68.4M
Net change in cash-$-31.87M$12.4M-$-21.54M$1.7M$28.3M
Cash at end of period$20M$51.8M$39.5M$61M$59.3M
Operating cash flow-$-43.44M-$-41.4M-$-52.4M-$-34.9M-$-34.63M
Capital expenditure-$-200K-$-30K-$-12.04M-$-41.37M-$-5.54M
Free cash flow-$-43.64M-$-41.42M-$-64.43M-$-76.27M-$-40.18M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Senti Biosciences, Inc.

        Senti Biosciences, Inc. is a pioneering company specializing in gene circuit technology. They focus on creating advanced cell and gene therapies that incorporate sophisticated gene circuits, essentially biological computers, to genetically reprogram cells. This allows the modified cells to interpret biological cues, make precise decisions, and react appropriately within their specific cellular surroundings. Their proprietary synthetic biology platform leverages readily available, "off-the-shelf" chimeric antigen receptor natural killer (CAR-NK) cells. This innovative approach is specifically designed to tackle formidable liquid and solid tumor cancers. Among their leading therapeutic candidates is SENTI-202. This "Logic Gated OR+NOT" off-the-shelf CAR-NK cell therapy is engineered to selectively identify and destroy acute myeloid leukemia (AML) cells, critically leaving healthy bone marrow unharmed. Another key program, SENTI-301, is a multi-armed, ready-to-use CAR-NK cell therapy being developed for the treatment of hepatocellular carcinoma (HCC). Additionally, SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy, aims to precisely eliminate colorectal cancer (CRC) cells without damaging the body's healthy tissues. Established in 2016, Senti Biosciences maintains its headquarters in South San Francisco, California.

        CEO
        Timothy K. Lu
        Employees
        39
        Beta
        2.05

        Explore

        Frequently asked questions

        What is the intrinsic value of Senti Biosciences, Inc. (SNTI)?

        InvestorsCraft does not currently publish an intrinsic value for SNTI. How the IC value is calculated.

        Is SNTI undervalued?

        InvestorsCraft does not publish an undervaluation signal for SNTI at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.